Application for the Analysis of Investment Fund Portfolios

[Abstract] An investment fund is a vehicle that collects the money of various citizens or companies to invest together. With a single investment, you can have different stocks or bonds in your portfolio. In addition, when doing it together with other investors, the sum is greater and allows access to the best managers and at a lower cost than if we did it individually. Once invested in a certain fund, we delegate to a manager the ability to decide where to invest. However, it is us, the investors, who will make the decision on which funds to invest in. Thanks to our application that gives us detailed and tailored information about the funds in our investment portfolio and our movements, making these decisions will be a much easier task. Our application also displays charts that allow us to compare the funds in our portfolio at a glance. The calculation of the metrics and the returns (fiscal, financial dependent on our transactions and financial of the fund) is one of the main objectives of our project, since they will help us determine the future of our investments.[Resumen] Un fondo de inversión es un vehículo que reúne el dinero de diversos ciudadanos o compañías para invertirlo de modo conjunto. Con una sola inversión, puedes tener distintas acciones o bonos en cartera. Además, al hacerlo junto con otros inversores, la suma es mayor y permite tener acceso a los mejores gestores y a un menor coste que si lo hiciésemos de modo individual. Una vez invertido en un determinado fondo, delegamos en un gestor la capacidad de decidir dónde invertir. Pero somos nosotros mismos, los inversores, los que tomaremos la decisión de en qué fondos invertir. Gracias a nuestra aplicación que nos da una información detallada y a medida de los fondos de nuestra cartera de inversión y de nuestros movimientos, tomar estas decisiones será una tarea mucho más fácil. Nuestra aplicación también muestra gráficas que nos permitirán comparar los fondos de nuestra cartera de un vistazo. El cálculo de las métricas y las rentabilidades (fiscal, financiera dependiente de nuestras transaccions y financiera del fondo) es uno de los principales objetivos de nuestro proyecto, ya que nos ayudarán a determinar el futuro de nuestras inversionesTraballo fin de grao (UDC.FIC). Enxeñaría informática. Curso 2019/202

Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models

The authors thank Medical Research Scotland and the Scottish Funding Council. This work was su pported by Medical Research Scotland [FRG353 to V.A.S.]; the FP7 -­‐ Directorate -­‐ General for Research and Innovation of the European Commission [EU HEALTH -­‐ F4 -­‐ 2012 -­‐ 305033 to Coordinating Action Systems Medicine -­‐ D.J.H.]; the Chief Scientist Office of Scotland [D.J.H.], the Scottish Funding Council [D.J.H. and S.P.L.]. Health Canada Scholarship (Indspire) [KEF], Scottish Overseas Research Student Award Scheme (University of Edinburgh)[KEF] and the Three Fires Award (Wikwemikong Board of Education)[KEF].Background: The dynamic changes that occur in protein expression after treatment of a cancer in vivo are poorly described. In this study we measure the effect of chemotherapy over time on the expression of a panel of proteins in ovarian cancer xenograft models. The objective was to identify phosphoprotein and other protein changes indicative of pathway activation that might link with drug response. Methods: Two xenograft models, platinum-responsive OV1002 and platinum-unresponsive HOX424, were used. Treatments were carboplatin and carboplatin-paclitaxel. Expression of 49 proteins over 14 days post treatment was measured by quantitative immunofluorescence and analysed by AQUA . Results: Carboplatin treatment in the platinum-sensitive OV1002 model triggered up-regulation of cell cycle, mTOR and DDR pathways, while at late time points WNT, invasion , EMT and MAPK pathways were modulated. Estrogen receptor-alpha (ESR1) and ERBB pathways were down-regulated early, within 24h from treatment administration. Combined carboplatin-paclitaxel treatment triggered a more extensive response in the OV1002 model modulating expression of 23 of 49 proteins. Therefore the cell cycle and DDR pathways showed similar or more pronounced changes than with carboplatin alone . In addition to expression of pS6 and pERK increasing, components of the AKT pathway were modulated with pAKT increasing while its regulator PTEN was down-regulated early. WNT signaling, EMT and invasion markers were modulated at later time points. Additional pathways were also observed with the NFκB and JAK/STAT pathways being up-regulated. ESR1 was down-regulated as was HER4, while further protein members of the ERB B pathway were upregulated late. By contrast, in the carboplatin-unresponsive HOX 424 xenograft, carboplatin only modulated expression of MLH1 while carboplatin-paclitaxel treatment modulated ESR1 and pMET.Publisher PDFPeer reviewe

Elucidating the Impact of Roseophage on Roseobacter Metabolism and Marine Nutrient Cycles

As the most abundant biological entities in marine environments, viruses are an important component of marine food webs. The activity of viruses contributes significantly to the mortality of marine microorganisms, ultimately influencing biological function and chemical composition of aquatic systems by impacting species composition and flow of carbon, nitrogen and other nutrients. Despite the growing recognition that viral activity contributes to marine biogeochemical cycles, the extent to which virus infection reshapes host metabolism and the effect of this alteration on the composition of host lysate remains poorly understood. Additionally, the degree to which natural bacterioplankton communities metabolise the released lysate material remains an open question. In this study, we use a Roseobacter lysogen, Sulfitobacter sp. CB2047, and its infecting phage as models to examine phage-host interactions in the marine environment. Specifically, this dissertation investigates the effect of superinfection of Sulfitobacter lysogens on resident prophage induction and its effect on accelerating the transfer of genetic material and increasing microbial genetic diversity. This work also characterizes the effect that phage infection has on reshaping host metabolic processes to provide building blocks for the synthesis of new virion particles and how this redirection of host metabolism affects the composition of material released as virus lysate after cell lysis. Finally, this dissertation examines how virus-derived lysates are metabolised by members of the natural bacterioplankton community and how this affects the consuming population’s metabolism. Results from our studies indicate that superinfection of Sulfitobacter lysogens increases prophage induction ~24-fold and increases Sulfitobacter diversity by up to 2%. Our results also indicate that phage infection significantly elevates host metabolism, redirecting ~75% of host resources from energy production to the production of new phage virions. Additionally, our results demonstrate that viral lysates are rich in small, labile nutrients that are readily utilized by natural bacterioplankton communities, significantly increasing their metabolite pools and nutrient turnover. Overall, this research provides an enhanced framework for understanding the role of marine viruses in shaping microbial genetic diversity and characterizes the impact that virus infections have on redirecting host metabolism as well as the availability and metabolism of nutrients to natural bacterioplankton communities

Biomarkers in systemic scelrosis

Systemic sclerosis (SSc; scleroderma) is a chronic multisystem autoimmune disease that includes prominent skin involvement in all patients and is characterized by fibrosis, inflammation, and microvascular injury of the skin and internal organs. Clinical trial design for patients with systemic sclerosis (SSc) has been confounded by the heterogeneity of disease progression and lack of objective outcome measures. This has hampered identification of therapies for patients who have frequently fatal fibrotic complications. Direct pulmonary complications are the leading cause of death in SSc. For clinical trials in patients with diffuse cutaneous SSc, identification of a pharmacodynamic biomarker associated with clinical improvement would allow for alternative approaches to trial design. Furthermore, identification of a diagnostic biomarker for SSc complicated by pulmonary arterial hypertension (SSc-PAH) would provide a reliable non-invasive method for diagnosis of pulmonary arterial hypertension. Through the combination of high throughput technologies and clinical information we have identified three preliminary biomarkers for SSc: i) Two pharmacodynamic biomarkers for diffuse skin disease (dcSSc), one in using mRNA from skin biopsies and one using proteomic profiles from sera; ii) a serum based proteomic classifier for the screening and diagnostic evaluation of pulmonary arterial hypertension in systemic sclerosis. We show these biomarkers can be applied to assess changes in skin disease in dSSc patients over time and with further development could be used to supplement or replace the physical examination assessment (Modified Rodnan Skin Score, MRSS) as an outcome measure in clinical trials for dcSSc patients. Routine use of these biomarkers in SSc clinical trial design could expand treatment options for a patient population that currently has few if any treatment options that slow progression of disease. Furthermore we identified a serum biomarker for the major SSc pulmonary complication, SSc-PAH. This diagnostic SSc-PAH biomarker has the potential to be used as a screening tool in order to reduce the need for unnecessary invasive diagnostic procedures. This non-invasive screening method could lead to early diagnosis thus improving patient survival and aid in clinical management of a complication for which there are several treatments but which is still frequently fatal.2018-06-15T00:00:00